NasdaqCM:UNCYBiotechs
Unicycive Therapeutics (UNCY) On FDA Setback Still Carries A Fair Value Debate
Unicycive Therapeutics (UNCY) is back in focus after the US Food and Drug Administration issued a Complete Response Letter on its resubmitted New Drug Application for oxylanthanum carbonate, keeping approval on hold over third party manufacturing issues.
See our latest analysis for Unicycive Therapeutics.
The FDA letter and the recent expansion of Unicycive Therapeutics' at-the-market program have coincided with sharp share price swings, including a 12.58% 1-day share price return, but 7-day...

